New hope for tough lymphomas: experimental drug GNC-038 enters human testing
NCT ID NCT05627856
First seen Nov 01, 2025 · Last updated May 20, 2026 · Updated 29 times
Summary
This early-phase study tests an experimental drug called GNC-038 in people with certain lymphomas (NK/T-cell lymphoma, AITL, and other non-Hodgkin lymphomas) that have returned or not responded to standard therapy. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Only 4 participants are enrolled in this small, open-label study.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, 510120, China
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510050, China
Conditions
Explore the condition pages connected to this study.